Advicenne receives reimbursement for Likozam® and reduces its debt

Advicenne has announced that its drug Likozam® will be reimbursed by social security in France starting June 12, 2026. This decision has a direct impact on the company's financial management. The end of the "Early Access" discounts will reduce Advicenne's debt to the French government by approximately €6 million. The officially set price is €92.24 for a 150 ml bottle of Likozam®.

This development also simplifies the dispensing of Likozam®, which is now available in pharmacies. Didier Laurens, CEO, expressed his satisfaction, highlighting the positive impact of this decision on the company's financial transparency and the support it provides to patients with rare epilepsies.